Clinical Data Psyched For Vilazodone NDA Filing In Second Half
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Clinical Data has kicked off what could prove to be a pivotal year with a flurry of activity, including a new financing, the sale of its Cogenix pharmacogenomics services arm, and the publication of important clinical trial results. But investors are more concerned with what's coming in a couple of months: results from a second pivotal trial for its lead therapeutic candidate vilazodone and the subsequent NDA filing